Skip to Main Content
Contribute Try STAT+ Today

A New York State panel has recommended that officials seek a supplemental Medicaid rebate for a pricey rare disease drug sold by Biogen (BIIB), marking only the third time such a move was proposed because a medicine may cause the state Medicaid program to exceed a cap on drug spending.

In a 14-to-0 vote last Thursday, the state’s Drug Utilization Review panel agreed that a rebate should be pursued for Spinraza, which is used to treat muscular spinal atrophy, an often-fatal genetic disease affecting muscle strength and movement. In its deadliest form, referred to as Type 1, the disease causes children to die by the time they turn 2 years old.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.